Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis

Abstract Background Sarilumab, an IL-6 receptor antagonist, is a first-line biologic disease-modifying anti-rheumatic drug for rheumatoid arthritis. The identification of genetic biomarkers as predictors of response to sarilumab could allow for a personalized treatment strategy to improve clinical o...

Full description

Bibliographic Details
Main Authors: Luis Sainz, Pau Riera, Patricia Moya, Sara Bernal, Jordi Casademont, Cesar Díaz-Torné, Ana Milena Millán, Hye Sang Park, Adriana Lasa, Hector Corominas
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Arthritis Research & Therapy
Subjects:
IL6R
Genetic variants
Sarilumab
Rheumatoid arthritis
Predictive factors
Online Access:https://doi.org/10.1186/s13075-023-03209-1

Internet

https://doi.org/10.1186/s13075-023-03209-1

Similar Items